Form 8-K - Current report:
SEC Accession No. 0001213900-22-071209
Filing Date
2022-11-10
Accepted
2022-11-10 16:24:09
Documents
13
Period of Report
2022-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea168440-8k_immucell.htm   iXBRL 8-K 31438
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 10, 2022 ea168440ex99-1_immucell.htm EX-99.1 15903
  Complete submission text file 0001213900-22-071209.txt   225367

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20221108.xsd EX-101.SCH 3227
4 XBRL LABEL FILE iccc-20221108_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20221108_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT ea168440-8k_immucell_htm.xml XML 3482
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 221377632
SIC: 2835 In Vitro & In Vivo Diagnostic Substances